Biomedical research on cannabis

(a) In general The Secretary of Health and Human Services (referred to in this section as the Secretary), in consultation with the Director of the National Institutes of Health, shall conduct or support research on the impacts of cannabis. (b) Topics The research conducted or supported under subsection (a) may include research on— (1) the effects of tetrahydrocannabinol on the human brain; (2) the efficacy of cannabis as a treatment for specific diseases and conditions, including any impact on chronic pain and post-traumatic stress disorder; (3) the impact of the use of cannabis on— (A) pulmonary function; (B) cardiovascular events; (C) cancer, including testicular, ovarian, transitional cell, and head, neck, and oral cancers, and chronic illnesses; (D) mania; (E) psychosis; (F) cognitive effects; and (G) cannabinoid hyperemesis syndrome; and (4) the identification of additional medical benefits, harms, and uses of cannabis. (c) Considerations In conducting or supporting the research under subsection (a), the Secretary may consider— (1) varying forms of cannabis, including— (A) full plants and extracts; and (B) different types of cannabis with significant variation in phenotypic traits and various ratios of tetrahydrocannabinol and cannabidiol in chemical composition; and (2) varying methods of cannabis delivery, including combustible and non-combustible inhalation and ingestion. (d) Annual reports Not later than 18 months after the date of enactment of this Act, and annually thereafter for the next 4 years, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, a report that includes an overview of the research conducted and supported under this section. (e) Funding In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $200,000,000 for each of fiscal years 2026 through 2030 to carry out this section.